Payer Perspectives on Coverage of Biomarker Testing in Cardiovascular Disease
payers are less able to rely on regulatory assessment of IVD and apply their own standards for coverage. [...]the Medicare contractor Noridian covers only lipid panels for CVD risk prediction, excluding "all non-lipid biomarkers including biochemical, hematologic, immunologic, and genetic biomarkers for CV risk assessment" (5)..
| Medienart: |
Artikel |
|---|
| Erscheinungsjahr: |
2017 |
|---|---|
| Erschienen: |
2017 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:63 |
|---|---|
| Enthalten in: |
Clinical chemistry - 63(2017), 1, Seite 258-260 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Tunis, Sean R [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Accuracy |
|---|
| doi: |
10.1373/clinchem.2016.268136 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
OLC198779933X |
|---|
| LEADER | 01000caa a2200265 4500 | ||
|---|---|---|---|
| 001 | OLC198779933X | ||
| 003 | DE-627 | ||
| 005 | 20230715013946.0 | ||
| 007 | tu | ||
| 008 | 170207s2017 xx ||||| 00| ||eng c | ||
| 024 | 7 | |a 10.1373/clinchem.2016.268136 |2 doi | |
| 028 | 5 | 2 | |a PQ20170301 |
| 035 | |a (DE-627)OLC198779933X | ||
| 035 | |a (DE-599)GBVOLC198779933X | ||
| 035 | |a (PRQ)c979-c3fb1df2c74ada4273b4284f6f81c1d78f720e38600b1c27940635182421030e0 | ||
| 035 | |a (KEY)0055889320170000063000100258payerperspectivesoncoverageofbiomarkertestingincar | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | 4 | |a 540 |a 610 |q DNB |
| 100 | 1 | |a Tunis, Sean R |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Payer Perspectives on Coverage of Biomarker Testing in Cardiovascular Disease |
| 264 | 1 | |c 2017 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ohne Hilfsmittel zu benutzen |b n |2 rdamedia | ||
| 338 | |a Band |b nc |2 rdacarrier | ||
| 520 | |a payers are less able to rely on regulatory assessment of IVD and apply their own standards for coverage. [...]the Medicare contractor Noridian covers only lipid panels for CVD risk prediction, excluding "all non-lipid biomarkers including biochemical, hematologic, immunologic, and genetic biomarkers for CV risk assessment" (5). | ||
| 650 | 4 | |a Stakeholders | |
| 650 | 4 | |a Apolipoproteins | |
| 650 | 4 | |a Lipids | |
| 650 | 4 | |a Accuracy | |
| 650 | 4 | |a Patients | |
| 650 | 4 | |a Biomarkers | |
| 650 | 4 | |a Cholesterol | |
| 650 | 4 | |a Science | |
| 650 | 4 | |a Diagnostic tests | |
| 650 | 4 | |a Decision making | |
| 650 | 4 | |a Collaboration | |
| 650 | 4 | |a Experts | |
| 650 | 4 | |a Research methodology | |
| 700 | 1 | |a Messner, Donna A |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |t Clinical chemistry |d Washington, DC : American Association for Clinical Chemistry, 1955 |g 63(2017), 1, Seite 258-260 |w (DE-627)129269115 |w (DE-600)80102-1 |w (DE-576)014459558 |x 0009-9147 |7 nnns |
| 773 | 1 | 8 | |g volume:63 |g year:2017 |g number:1 |g pages:258-260 |
| 856 | 4 | 1 | |u http://dx.doi.org/10.1373/clinchem.2016.268136 |3 Volltext |
| 856 | 4 | 2 | |u http://search.proquest.com/docview/1862040809 |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a SYSFLAG_A | ||
| 912 | |a GBV_OLC | ||
| 912 | |a SSG-OLC-CHE | ||
| 912 | |a SSG-OLC-PHA | ||
| 912 | |a SSG-OLC-DE-84 | ||
| 912 | |a GBV_ILN_31 | ||
| 912 | |a GBV_ILN_69 | ||
| 912 | |a GBV_ILN_2006 | ||
| 912 | |a GBV_ILN_2011 | ||
| 912 | |a GBV_ILN_4012 | ||
| 912 | |a GBV_ILN_4112 | ||
| 912 | |a GBV_ILN_4125 | ||
| 912 | |a GBV_ILN_4219 | ||
| 912 | |a GBV_ILN_4305 | ||
| 951 | |a AR | ||
| 952 | |d 63 |j 2017 |e 1 |h 258-260 | ||